AIM ImmunoTech, Inc. (AIM)
0.1626
-0.01
(-4.35%)
USD |
NYAM |
Oct 22, 16:00
0.1626
0.00 (0.00%)
After-Hours: 16:27
AIM ImmunoTech Net Income (Quarterly) : -3.788M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.788M |
| March 31, 2026 | -3.023M |
| December 31, 2025 | -4.175M |
| September 30, 2025 | -3.284M |
| June 30, 2025 | -2.794M |
| March 31, 2025 | -3.705M |
| December 31, 2024 | -5.967M |
| September 30, 2024 | -3.70M |
| June 30, 2024 | -1.836M |
| March 31, 2024 | -5.817M |
| December 31, 2023 | -12.58M |
| September 30, 2023 | -7.816M |
| June 30, 2023 | -4.909M |
| March 31, 2023 | -3.661M |
| December 31, 2022 | -4.389M |
| September 30, 2022 | -6.385M |
| June 30, 2022 | -4.851M |
| March 31, 2022 | -3.82M |
| December 31, 2021 | -5.846M |
| September 30, 2021 | -3.826M |
| June 30, 2021 | -5.876M |
| March 31, 2021 | -3.579M |
| December 31, 2020 | -3.934M |
| September 30, 2020 | -3.306M |
| June 30, 2020 | -3.37M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.808M |
| December 31, 2019 | -1.063M |
| September 30, 2019 | -2.948M |
| June 30, 2019 | -2.036M |
| March 31, 2019 | -3.368M |
| December 31, 2018 | -1.607M |
| September 30, 2018 | -3.078M |
| June 30, 2018 | -2.415M |
| March 31, 2018 | -2.713M |
| December 31, 2017 | -1.993M |
| September 30, 2017 | -1.252M |
| June 30, 2017 | -2.193M |
| March 31, 2017 | -2.821M |
| December 31, 2016 | -1.173M |
| September 30, 2016 | -2.862M |
| June 30, 2016 | -1.303M |
| March 31, 2016 | -2.164M |
| December 31, 2015 | -3.137M |
| September 30, 2015 | -3.803M |
| June 30, 2015 | -4.845M |
| March 31, 2015 | -3.445M |
| December 31, 2014 | -4.456M |
| September 30, 2014 | -4.202M |
| June 30, 2014 | -4.956M |
| March 31, 2014 | -3.836M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.026M |
| Total Expenses (Quarterly) | 3.814M |
| EPS Diluted (Quarterly) | -0.2213 |
| Enterprise Value | -1.115M |
| Gross Profit Margin (Quarterly) | -1.95K% |
| Profit Margin (Quarterly) | -14.57K% |
| Earnings Yield | -2.36K% |
| Normalized Earnings Yield | -2242.87 |